Accessing the Cells

Mesenchymal Stem Cells (MSCs) are adult multipotent stem cells with anti-inflammatory, immunomodulatory and regenerative properties. They exist in various tissues in the body, such as bone marrow and fat, and are present from birth. MSCs have been shown to reduce harmful inflammation by regulating the immune response and to help restore old and damaged cells via their tissue regenerative properties. After their discovery in the 1960s, they have been intensely studied by researchers in laboratories and in clinical trials all over the world. MSCs are believed to hold great promise in treatment of many severe and incurable diseases.  

Bone marrow derived MSCs have a long history of use in scientific research. A meta-analysis published in 2021 reviewed 62 randomised clinical trials and concluded that MSC treatment appears safe compared to placebo. No serious adverse events were discovered across the included studies. 

Clinical trials are research studies performed on people that are aimed at evaluating a medical, surgical, or behavioral intervention. They are the primary way that researchers find out if a new treatment, such as a new drug, is safe and effective in people.

Autologous stem cell treatments use cells derived from the patient's own body. In practice, this often involves extracting MSCs from the fat tissue and injecting the patient with a concentrate including stem cells from the fat. This treatment option is widespread today since it is not classified as a medicinal product. This however also means that there is no control from medical authorities such as EMA and FDA.

Allogeneic stem cell treatments use the cells obtained from a donor.

There are various advantages with allogeneic MSC treatments produced by companies that follow the EU or US regulations. The quality is strictly regulated and controlled, meaning that we can be certain that the patient receives the intended amount and potency of cells. There is data indicating that MSCs from younger people are more potent than from older ones. One donor can provide enough cells to more than 100 patients.

MSCs are utilised or under investigation for a broad spectrum of conditions. As a manufacturer, we advise anyone considering stem cell therapies or participation in clinical trials to seek guidance from their healthcare provider.

MSCs therapy can be administered through various methods. Typically, these treatments are given either systemically via intravenous infusion or through a local injection. 

Currently, we do not offer any stem cell treatments for commercial use. Our Mesenchymal Stem Cells (MSCs) are exclusively available to eligible participants enrolled in our subsidiary Cellcolabs Clinical or our partners clinical trials.